EUCTR2008-000045-59-BE进行中（未招募）1 期
Multicentre, controlled, randomized, investigator-blinded, comparitive study of oral Mesalazine 4 g per day Once daily versus 4 g per day in Two divided doses in patients with Active Ulcerative Colitis. - MOTUS
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Ferring SAS
- 入组人数
- 398
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Age over 18 years
- •- Newly diagnosed or relapsing mild to moderate ulcerative colitis with disease extension beyond rectum (of at least 12-18 cm from the anorectal junction). All patients must have had at least one total colonoscopy in their disease history (within the previous 5 years).
- •- Disease activity will be assessed on the 7 days before inclusion and according to ulcerative colitis disease activity index (UC-DAI) score. The UC-DAI score will be from 3 to 8 (mild: 3-5 or moderate: 6-8).
- •- Men or non-pregnant women.
- •- Women with childbearing potential must be using a contraceptive method judged effective by the investigator.
- •- Oral maintenance treatment with azathioprine or 6-mecraptopurine (taken for at least 6 months and continued at the same dose throughout the study) is permitted.
- •- informed consent given.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- proctitits (less than 12-18 cm from the anorectal junction
- •- previous colonic surgery.
- •- previous failed to respond to steroids within the previous year.
- •- Non-response to rectal 5-ASA therapy or to oral 5-ASA therapy at dose > 3/day for induction of remission within the previous year.
- •- Current relapse lasting more than 6 weeks (from what patient says).
- •- Severe/fulminant ulcerative colitis
- •- Evidence of other forms of inflammatory bowel disease or infectious disease.
- •- Allergy to aspirin or salicylate derivatives.
- •- The following treatment will be forbidden during the study (if present at selection, a wash-out will be necessary):
- •* Loperamide and other antidiarrheal agents, mucilages, antibiotics
- •(metronidazole) and ciproflocacin): 1 week wash-out.
- •* Oral steroids: 4 weeks wash-out.
- •* Rectal steroids: 2 weeks wash-out
- •* Repeated treatment (> 3 days of use) of non-steroidal anti-inflammatory drugs
- •(NSAID) oral or rectal route: 1 week wash-out (aspirin for cardioprotection is allowed.
- •* Sulfasalzine > 4g or mesalazine or 4-ASA at a higher dose than what it is
- •permitted in the local formulary or standard care for maintenance treatment: 4
- •weeks wash-out.
- •* Immunomodulating/suppressing drugs: 3 month for wash-out (except for
- •patients maintained on azathioprine or 6-mercaptopuring-see above)
- •- Known significant hepatic or renal function abnormalities.
- •- Moderate/severe abnormal renal, hepatic or blood count tests defineda as: creatinine plasma value > 1.5 x ULN or white blood cells <3500/mm3 or > 15000/mm3 or platelets <100000/mm3 or > 800000/mm3 or ASAT/ALAT >3 x ULN or GGT/Alkalin Phosphatases > 3 x ULN (Primary Sclerosing Cholangitis is not an exclusion criteria).
- •- History or physical examination findings indicative of active alcohol or drug abuse.
- •- Pregnancy or breast-feeding
- •- History of disease, including mental/emotional disorder, that might interfere with their participation in the study.
- •- Participation in another clinical study in the last 3 months.
- •- Inability to comply with the protocol requirements.
- •- Inability to fill in the diary cards
研究者
相似试验
进行中（未招募）
不适用
Multicentre, controlled, randomized, investigator-blinded, comparative study of oral Mesalazine 4g per day Once daily versus 4g per day in Two divided doses in patients with active Ulcerative colitiS - MOTUSEUCTR2008-000045-59-NLFerring SAS398
进行中（未招募）
不适用
Multicentre, controlled, randomized, investigator-blinded, comparative study of oral mesalazine 4g per day once daily versus 4g per day in two divided doses in patients with active ulcerative colitis. - MOTUSPatients with mild to moderate active ulcerative colitisMedDRA version: 9.1Level: LLTClassification code 10058816Term: Colitis ulcerative acute episodeEUCTR2008-000045-59-GBFerring Pharmaceuticals Ltd.398
进行中（未招募）
1 期
Multicentre, controlled, randomized, investigator-blinded, comparative study of oral Mesalazine 4g per day Once daily versus 4g per day in Two divided doses in patients with active Ulcerative colitiS - MOTUSEUCTR2008-000045-59-FRFerring SAS398
已完成
3 期
Multicentre, controlled, randomised, investigator-blinded, comparative study of oral Mesalazine 4g per day Once daily versus 4g per day in Two divided doses in patients with active Ulcerative colitiS (MOTUS study)10017943ulcerative colitisIBDNL-OMON32538Ferring40
进行中（未招募）
不适用
Study to compare the Metvix® efficacy in eliminating the actinic (solar) keratoses when activated by the natural daylight or by a red lampMild and/or moderate Actinic KeratosesMedDRA version: 16.0Level: HLTClassification code 10020648Term: HyperkeratosesSystem Organ Class: 100000004858EUCTR2013-000973-54-DEGalderma R&D SNC120